Investigation of megakaryopoiesis in myelosuppressed bone marrow using immunogold-silver staining (IGSS).
To determine the frequencies and differential counts of megakaryocytes after cytoreductive treatment in nucleated low-density (1.060 g/ml) bone marrow cells (BMNC) of dogs an immunogold-silver staining (IGSS) technique with the lineage specific monoclonal antibody 2F9 was established. This antibody recognizes the glycoprotein IIb/IIIa complex expressed on the surface of canine megakaryocytes and platelets. The IGSS technique enables not only the detection of megakaryocytes occurring at a low frequency (0.1-0.2%), but also the discrimination between the different maturation stages of megakaryocytes due to cell size, nuclear morphology and cytoplasmic staining. By the use of this technique, small lymphoid megakaryocytic cells were identified. Comparable numbers of megakaryocyte colony-forming cells in 2F9-depleted and nondepleted BMNC suspensions (25.7 +/- 5.0 vs. 25.3 +/- 5.1 Meg-CFC/10(5) BMNC) indicate that these small 2F9 positive cells are nonclonogenic precursors of megakaryoblasts. To prove the applicability of IGSS, serial examinations of bone marrow samples from dogs treated with recombinant human interleukin-6 (IL-6) after exposure to 2.4 Gy total body irradiation (TBI) were performed. The results of the microscopic evaluation indicate that, in the recovery phase after TBI, IL-6 induced an earlier and stronger increase in megakaryocyte frequency in comparison to the control. Interestingly, all maturation stages of the megakaryocytic lineage took part in this IL-6 induced improvement of megakaryocyte recovery.
Selig
C
C
Institute for Clinical Physiology and Occupational Medicine, University of Ulm, Germany.
Kreja
L
L
Nothdurft
W
W
D000818:Animals; D000911:Antibodies, Monoclonal; D001853:Bone Marrow / Q000187:drug effects / Q000528:radiation effects; D001854:Bone Marrow Cells; D002455:Cell Division; D004285:Dogs; D006410:Hematopoiesis / Q000187:drug effects / Q000528:radiation effects; D006801:Humans; D015850:Interleukin-6 / Q000494:pharmacology; D007700:Kinetics; D008533:Megakaryocytes / Q000166:cytology* / Q000187:drug effects / Q000528:radiation effects; D010976:Platelet Count / Q000187:drug effects / Q000528:radiation effects; D011994:Recombinant Proteins / Q000494:pharmacology; D012834:Silver; D013194:Staining and Labeling / Q000379:methods; D013997:Time Factors; D014916:Whole-Body Irradiation
D000911:Antibodies, Monoclonal; D015850:Interleukin-6; D011994:Recombinant Proteins; D012834:Silver